Biocryst Pharmaceuticals (BCRX) closed at $7.69 on November 6, 2026, up 0.8% from the previous close, on volume of 3,897,421 shares (30-day average 5,645,194).
Data as of November 6, 2026.
6-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 6, 2026. See the 10 largest for 30, 60 and 90 days
Analysts Offer Insights on Healthcare Companies: BioCryst (BCRX) and Gilead Sciences (GILD)
TipRanks (Thu, 5-Nov 9:41 AM ET)
Wedbush Sticks to Its Buy Rating for BioCryst (BCRX)
TipRanks (Thu, 5-Nov 7:56 AM ET)
BioCryst Earnings Call Highlights ORLADEYO Growth
TipRanks (Wed, 4-Nov 7:20 PM ET)
BioCryst to Present at Upcoming Investor Conferences
Globe Newswire (Wed, 4-Nov 4:01 PM ET)
BCRX Posts Q3 Operating Profit of $53.3M as ORLADEYO Pellets Expand to Ages 12+
Market Chameleon (Wed, 4-Nov 3:35 AM ET)
BioCryst Reports Strong Third-Quarter Results and ORLADEYO Growth
TipRanks (Wed, 4-Nov 7:35 AM ET)
BioCryst Pharmaceuticals GAAP EPS of $0.14 beats by $0.06, revenue of $180.29M beats by $14.61M
Seeking Alpha News (Wed, 4-Nov 7:04 AM ET)
BioCryst Reports Third Quarter 2026 Financial Results
Globe Newswire (Wed, 4-Nov 7:00 AM ET)
Here are the major earnings before the open Wednesday
Seeking Alpha News (Tue, 3-Nov 6:00 PM ET)
BioCryst Pharmaceuticals Q3 2026 Earnings Preview
Seeking Alpha News (Tue, 3-Nov 11:04 AM ET)
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
Biocryst Pharmaceuticals trades on the NASDAQ stock market under the symbol BCRX.
As of November 6, 2026, BCRX stock price climbed to $7.69 with 3,897,421 million shares trading.
BCRX has a beta of 0.67, meaning it tends to be less sensitive to market movements. BCRX has a correlation of 0.03 to the broad based SPY ETF.
BCRX has a market cap of $1.97 billion. This is considered a Small Cap stock.
Last quarter Biocryst Pharmaceuticals reported $180 million in Revenue and $.14 earnings per share. This beat revenue expectation by $14 million and exceeded earnings estimates by $.03.
In the last 3 years, BCRX traded as high as $11.31 and as low as $4.03.
The top ETF exchange traded funds that BCRX belongs to (by Net Assets): VTI, XBI, IWM, VB, VXF.
BCRX has underperformed the market in the last year with a return of +9.4%, while the SPY ETF gained +10.8%. In the last 3 month period, BCRX fell short of the market, returning -17.3%, while SPY returned -4.1%. However, in the most recent 2 weeks BCRX has outperformed the stock market by returning +0.5%, while SPY returned -3.2%.
BCRX support price is $7.40 and resistance is $7.86 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BCRX shares will trade within this expected range on the day.
